Resultados de la búsqueda 51-60 of 4118 for 구글찌라시 を 13242136 を텔@adtopkingををSEO백링크ををを텔@adtopkingををを구글등록ををを
Acalabrutinib is FDA approved for treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma. Durvalumab is FDA approved for treatment in lung ...
Mayo Clinic tiene uno de los centros médicos más grandes y experimentados en los Estados Unidos, con sedes en Arizona, Florida y Minnesota. El personal, que ...
Jacksonville, Fla. This randomized phase II trial studies how well olaparib, cediranib maleate, and standard chemotherapy work in treating patients with small ...
This randomized phase II trial studies how well olaparib, cediranib maleate, and standard chemotherapy work in treating patients with small cell lung cancer.
-Collect data, images, from patients undergoing surgical treatment of hip disorders (we will not be collecting social security numbers to send to Washington ...
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia ...
The natural course of autosomal dominant polycystic kidney disease (ADPKD) is highly variable and typically characterized by progressive enlargement of cysts ...
Rochester, Minn. The purposes of this study are (i) to obtain and study biospecimens from patients with breast cancer that has either spread out of the breast ...
The purpose of this study is to evaluate olaparib and temozolomide in treating patients with uterine leiomyosarcoma (LMS) that has spread to other places of ...
Although survivorship recommendations have been developed in areas such as lymphoma and stem cell transplant, the long-term effects of CAR-T therapy are ...
Mayo Clinic no respalda compañías ni productos. Las recaudaciones de los avisos comerciales financian nuestra misión sin fines de lucro.
Consulta estos éxitos de venta y ofertas especiales en libros y boletines informativos de Mayo Clinic Press.
¿Te gustaría hacer una donación deducible de impuestos y ser parte de una investigación de vanguardia y de una atención médica que transforma la medicina?